

Intervention strategies in the glycation pathway with methylglyoxal as the primary target

Citation for published version (APA):

van den Eynde, M. D. G. (2024). *Intervention strategies in the glycation pathway with methylglyoxal as the primary target*. [Doctoral Thesis, Maastricht University]. Maastricht University. <https://doi.org/10.26481/dis.20240326me>

Document status and date:

Published: 01/01/2024

DOI:

[10.26481/dis.20240326me](https://doi.org/10.26481/dis.20240326me)

Document Version:

Publisher's PDF, also known as Version of record

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

Impact statement

Future perspectives and scientific impact

The treatment of multifactorial chronic diseases like diabetes is a continuing struggle. In recent years large advances have been made. In diabetes, treatments with metformin, GLP-1 receptor agonists, and SGLT-2 inhibitors, have greatly progressed disease management^{65,66}. However, the increasing prevalence of diabetes, accompanied by many micro- and macrovascular complications, requires a continuous improvement of treatments and more focus on prevention and personalized healthcare, in combination with improved self-management⁶⁷.

As mentioned in the introduction, the WHO states, *“Diabetes can be treated and its consequences avoided or delayed with diet, physical activity, medication and regular screening and treatment for complications”*. In our research we search for new perspectives and new interventions strategies in the glycation pathway.

A reduction in glycation could relieve part of the burden of obesity and diabetes. However, there are currently no clinical implementations of treatments focusing on the excessive endogenous production of dicarbonyls and consequent accumulation of advanced glycation endproducts (AGEs). In our research we studied the effect of a weight loss, exercise, flavonoid, and pyridoxamine intervention trial for their potential as strategies to inhibit the glycation pathway.

The treatment of complex metabolic diseases without a single molecular target and many interrelated pathways is a difficult feat. When focusing on the reduction of dicarbonyl species and AGEs, we found many reassuring effects in our intervention studies. These clinical studies, as described in this thesis, show that it is possible to reduce dicarbonyl stress and glycation in humans, without apparent side effects. Pyridoxamine and quercetin both show a 10% reduction in plasma MGO, accompanied by positive effects on markers of inflammation and endothelial dysfunction. Pyridoxamine also shows promise with regard to the inhibition of AGEs, but we did not find effects on insulin sensitivity or vascular function. In comparison, the effect size of MGO reduction by quercetin and pyridoxamine of 10% is similar to that what we found in our weight loss intervention. Our weight loss intervention study shows significant effects on fasting MGO and postprandial MGO levels. In contrast, high intensity exercise did not reduce glycation markers.

Many cohort and experimental studies have established the relation between glycation markers and vascular complications. It is reassuring that we were able to reduce dicarbonyl stress and glycation markers in our clinical studies. These data serve as a basis for future interventions; the focus could thereby shift towards treatment effects on

metabolic and vascular function as a consequence of lower dicarbonyl stress. Furthermore, higher dosages and longer duration of treatment should be considered in order to improve efficacy. Individuals with increased MGO stress, such as in diabetes, could benefit the most.

With regard to the prevention and treatment of diabetic complications, I believe the most important question is that of effect size. The evidence showing associations between dicarbonyl stress, AGEs, and disease progression is abundant and irrefutable^{57,60,68}. Based on the studies described in the thesis, we now know it is possible to effectively target MGO in apparently healthy individuals. The question remains what the treatment effect of a nutraceutical or lifestyle intervention on plasma MGO should be, to achieve an improved disease outcome in the long term.